Literature DB >> 16022953

Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction.

Lynn A Sleeper1, Krishnan Ramanathan, Michael H Picard, Thierry H Lejemtel, Harvey D White, Vladimir Dzavik, Deborah Tormey, Nancy E Avis, Judith S Hochman.   

Abstract

OBJECTIVES: Our goal was to describe the functional status of cardiogenic shock survivors, identify the correlates of cardiogenic shock, and compare global quality of life and functional status of patients randomly assigned to treatment with emergency revascularization (ERV) versus initial medical stabilization (IMS).
BACKGROUND: Historically, the hospital survival rate of patients with cardiogenic shock complicating acute myocardial infarction (MI) has been very low. Shock survivors are salvaged from a critically ill state, and their later functional status is not well documented. The SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK (SHOCK) trial showed significantly improved one-year survival after ERV compared with IMS.
METHODS: The SHOCK trial survivors completed interviews at 2 weeks after discharge and at 6 and 12 months after MI. Functional status assessment included the Multidimensional Index of Life Quality and New York Heart Association (NYHA) congestive heart failure functional class.
RESULTS: Eighty-seven percent of one-year survivors of the SHOCK trial were in NYHA functional class I or II. Between two weeks after discharge and one year after MI, improvement was similar in the two treatment groups (18% overall), but fewer patients remained stable (44% vs. 71%), and more patients worsened or died (34% vs. 15%) in the IMS group compared with those assigned to ERV. Assignment to ERV was the only independent predictor of outcome at one year.
CONCLUSIONS: Although one-year mortality after ERV is still high (54%), most survivors have good functional status. The ERV patients have a lower rate of deterioration than IMS patients. The level of recovery for shock patients undergoing ERV is similar to that of historical controls not in cardiogenic shock undergoing elective revascularization.

Entities:  

Mesh:

Year:  2005        PMID: 16022953     DOI: 10.1016/j.jacc.2005.01.061

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

1.  Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction.

Authors:  Krishnan Ramanathan; Michael E Farkouh; John E Cosmi; John K French; Shannon M Harkness; Vladimír Džavík; Lynn A Sleeper; Judith S Hochman
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

2.  Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction.

Authors:  Judith S Hochman; Lynn A Sleeper; John G Webb; Vladimir Dzavik; Christopher E Buller; Philip Aylward; Jacques Col; Harvey D White
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

Review 3.  [Infarct-related cardiogenic shock : Prognosis and treatment].

Authors:  R Prondzinsky; H Lemm; A Geppert; M Buerke; M Russ; K Werdan
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-02       Impact factor: 0.840

4.  Sex and Gender Disparities in the Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Older Adults.

Authors:  Saraschandra Vallabhajosyula; Saarwaani Vallabhajosyula; Shannon M Dunlay; Sharonne N Hayes; Patricia J M Best; Jorge A Brenes-Salazar; Amir Lerman; Bernard J Gersh; Allan S Jaffe; Malcolm R Bell; David R Holmes; Gregory W Barsness
Journal:  Mayo Clin Proc       Date:  2020-09       Impact factor: 7.616

Review 5.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Julia Schumann; Eva C Henrich; Hellen Strobl; Roland Prondzinsky; Sophie Weiche; Holger Thiele; Karl Werdan; Stefan Frantz; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29

6.  Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model.

Authors:  Husam Abdel-Qadir; Idan Roifman; Harindra C Wijeysundera
Journal:  CMAJ Open       Date:  2015-12-09

Review 7.  [New pharmacological treatment approaches to cardiogenic shock].

Authors:  M Buerke; M Russ; K Werdan
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

8.  Evidence-based Management of Cardiogenic Shock After Acute Myocardial Infarction.

Authors:  Karl Werdan; Martin Russ; Michael Buerke; Roland Prondzinsky; Sebastian Dietz
Journal:  Interv Cardiol       Date:  2013-08

9.  The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock.

Authors:  Grégoire Muller; Erwan Flecher; Guillaume Lebreton; Charles-Edouard Luyt; Jean-Louis Trouillet; Nicolas Bréchot; Matthieu Schmidt; Ciro Mastroianni; Jean Chastre; Pascal Leprince; Amedeo Anselmi; Alain Combes
Journal:  Intensive Care Med       Date:  2016-01-29       Impact factor: 17.440

Review 10.  Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.

Authors:  Susanne Unverzagt; Michael Buerke; Antoinette de Waha; Johannes Haerting; Diana Pietzner; Melchior Seyfarth; Holger Thiele; Karl Werdan; Uwe Zeymer; Roland Prondzinsky
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.